Acila Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 07-07-2024
- Paid Up Capital ₹ 0.34 M
as on 07-07-2024
- Company Age 45 Year, 10 Months
- Last Filing with ROC 31 Mar 2015
- Open Charges ₹ 0.60 M
as on 07-07-2024
- Revenue %
(FY 2015)
- Profit 16.67%
(FY 2015)
- Ebitda 16.67%
(FY 2015)
- Net Worth -29.77%
(FY 2015)
- Total Assets %
(FY 2015)
About Acila Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2015. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.34 M.
The company currently has active open charges totaling ₹0.60 M.
Bappaditya Majumdar, Pijush Bhowmick, and Chandrani Chakraborty serve as directors at the Company.
- CIN/LLPIN
U24231WB1979PTC031871
- Company No.
031871
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Feb 1979
- Date of AGM
30 Sep 2015
- Date of Balance Sheet
31 Mar 2015
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Acila Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bappaditya Majumdar  | Director | 27-Jul-2012 | Current |
| Pijush Bhowmick | Director | 03-Jun-1999 | Current |
| Chandrani Chakraborty | Director | 03-Jun-1999 | Current |
Financial Performance of Acila Pharmaceuticals.
Acila Pharmaceuticals Pvt Ltd, for the financial year ended 2015, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 16.67% increase in profit. The company's net worth observed a substantial decline by a decrease of 29.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Acila Pharmaceuticals?
Unlock access to Acila Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Acila Healthcare Private LimitedActive 13 years 9 monthsBappaditya Majumdar and Chandrani Chakraborty are mutual person
- Ajoy Hosiery Manufacturing Private LimitedActive 23 years 8 months
Chandrani Chakraborty is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 28 Aug 1980 | ₹0.60 M | Open |
How Many Employees Work at Acila Pharmaceuticals?
Unlock and access historical data on people associated with Acila Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Acila Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Acila Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
